Prenetics Global (NASDAQ:PRE) CEO Danny Sheng Wu Yeung Purchases 17,181 Shares of Stock

Key Points

• CEO Danny Sheng Wu Yeung purchased 17,181 shares of Prenetics Global at an average price of $21.23, investing approximately $364,753 and increasing his position by 18.04%. He also bought 7,500 shares earlier in August.
• Prenetics shares rose 8.0% to $21.82, near their 52-week high of $23.63. The company beat quarterly EPS expectations but missed revenue estimates and remained unprofitable.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $34.25, although one research firm maintains a sell rating.

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) CEO Danny Sheng Wu Yeung bought 17,181 shares of the stock in a transaction dated Monday, August 24th. The stock was bought at an average price of $21.23 per share, with a total value of $364,752.63. Following the acquisition, the chief executive officer owned 112,416 shares in the company, valued at approximately $2,386,591.68. This represents a 18.04% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Danny Sheng Wu Yeung also recently made the following trade(s):

• On Thursday, August 20th, Danny Sheng Wu Yeung bought 7,500 shares of Prenetics Global stock. The stock was bought at an average price of $18.31 per share, for a total transaction of $137,325.00.

Prenetics Global Trading Up 8.0%

Shares of NASDAQ:PRE traded up $1.62 during midday trading on Monday, hitting $21.82. The stock had a trading volume of 417,652 shares, compared to its average volume of 135,502. Prenetics Global Limited has a 1 year low of $7.18 and a 1 year high of $23.63. The stock has a 50 day moving average price of $19.07 and a two-hundred day moving average price of $18.90. The company has a market capitalization of $368.19 million, a PE ratio of -5.25 and a beta of 0.26.

Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.31. The firm had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. As a group, equities analysts expect that Prenetics Global Limited will post -1.86 EPS for the current year.

Institutional Investors Weigh In On Prenetics Global

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN acquired a new stake in shares of Prenetics Global during the 4th quarter valued at $47,000. State of Wyoming acquired a new stake in Prenetics Global during the first quarter valued at $48,000. JPMorgan Chase & Co. purchased a new position in Prenetics Global in the third quarter valued at about $65,000. Operose Advisors LLC acquired a new position in Prenetics Global in the 2nd quarter worth about $129,000. Finally, Manatuck Hill Partners LLC purchased a new stake in shares of Prenetics Global during the 4th quarter worth about $170,000. 25.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PRE. Benchmark raised their price objective on Prenetics Global from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prenetics Global in a report on Friday, July 17th. Finally, Wall Street Zen raised shares of Prenetics Global from a "sell" rating to a "hold" rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $34.25.

About Prenetics Global

Prenetics Global NASDAQ: PRE is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source